Ensysce Biosciences Acquires Cy Biopharma, Secures Up to $77 Million to Advance Orphan-Designated CRPS Therapy
核心洞察
Ensysce Biosciences completed the acquisition of Cy Biopharma (搜索), adding clinical-stage candidate CY200 (搜索) for Complex Regional Pain Syndrome (搜索) (CRPS) to its pipeline.
The transaction includes up to $77 million in financing through a cash contribution, private placement, and milestone-based tranche led by Ally Bridge Group (搜索).
CY200 (搜索) has received FDA Orphan Drug Designation, and funding is expected to support the program through Phase 2 proof-of-concept data and into registrational planning.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced on August 6, 2026, that it has completed the acquisition of Cy Biopharma (搜索), Inc., a privately held clinical-stage biotechnology company developing novel neuroplastogenic therapies with an initial focus on complex pain. Concurrent with the acquisition, Ensysce entered into a definitive agreement for a private placement financing that, together with Cy Biopharma's pre-acquisition cash, represents total funding of up to $77 million.
The transaction brings clinical-stage drug candidate CY200 (搜索) into Ensysce's portfolio. CY200 is being developed for Complex Regional Pain Syndrome (搜索) Type 1 (CRPS Type 1) and has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). The financing is expected to fund CY200 through topline Phase 2 proof-of-concept data and into registrational development.
Financing Structure and Key Investors
The financing package comprises three components: approximately $17.1 million in cash from Cy Biopharma (搜索)'s pre-acquisition convertible note financing, a private placement expected to yield approximately $21.5 million at initial closing, and up to $38.6 million in a follow-on tranche contingent upon achievement of a clinical trial milestone. The private placement involves the sale of Series C non-voting convertible preferred stock, with a conversion ratio of preferred to common at 1:1,000.
The private placement was led by Ally Bridge Group (搜索), with participation from Perceptive Advisors, Dellora Investments, Ikarian Capital, and Adage Capital Partners, L.P.
CY200 (搜索) and the Neuroplastogenic Approach
CY200 (搜索) represents a neuroplastogenic approach to treating complex pain, an area that Cy Biopharma (搜索) has pursued beyond traditional mood disorder applications. The program targets CRPS Type 1, a devastating chronic pain condition for which there is currently no approved therapy. The company noted that the pain market for this indication is valued at over $1 billion.
The FDA Orphan Drug Designation for CY200 (搜索) is expected to provide critical regulatory and commercial advantages as development advances. The proceeds are intended to support a randomized Phase 2 clinical trial assessing the efficacy, safety, and tolerability of CY200 for symptom alleviation in participants with CRPS Type 1.
Leadership Perspective
"Cy Biopharma (搜索)'s neuroplastogenic approach to complex pain was the most compelling opportunity we evaluated, and the Board of Directors of Ensysce believes this acquisition represents a significant value creation opportunity for Ensysce stockholders," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce. "The clinical data supporting CY200 (搜索) and Cy Biopharma's approach to treating the devastating condition of Complex Regional Pain Syndrome (搜索) reinforced our conviction for this program."
Dr. Kirkpatrick added that the concurrent private placement financing "was intentionally sized to support Cy Biopharma (搜索)'s immediate strategic objectives while maintaining financial discipline, and allow Cy Biopharma to progress its lead candidate in a pain market valued over $1 billion for which there is currently no approved therapy."
Continued Advancement of PF614-MPAR
Ensysce also stated its intention to continue advancing its PF614-MPAR opioid safety program. The PF614-MPAR-102 study is ongoing with financial support from the National Institute on Drug Abuse (NIDA). PF614-MPAR represents what the company describes as a fundamentally new approach to opioid safety.
Ownership Restructuring
The transaction significantly reshapes Ensysce's capital structure. Following shareholder approval for conversion of the Series C Preferred Stock into common shares under Nasdaq rules, former Cy Biopharma (搜索) shareholders are expected to own approximately 74.94% of the combined company, underscoring the scale of the acquisition and associated financing.
Upcoming Milestones
Key events on the horizon include the expected initial closing of the private placement on August 7, 2026, progress toward the clinical milestone required to unlock the additional $38.6 million financing tranche, topline Phase 2 results for CY200 (搜索) in CRPS Type 1, and the shareholder vote required to approve conversion of the Series C Preferred Stock.